BioSpace News Archive

Epizyme, Inc. shared preclinical data and the Phase 1/1b trial design for EZM0414, the Company’s novel, first-in-class, oral SETD2 inhibitor, an investigational agent being developed for the treatment of adult patients with relapsed or refractory multiple myeloma or with diffuse large B-cell lymphoma.

Orca Bio, a clinical-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, announced positive clinical data on its lead investigational cell therapy, Orca-T, were presented at the American Society of Hematology Annual Meeting.

Kite, a Gilead Company, announced updated two-year results from ZUMA-5, a global, multicenter, single-arm, open-label Phase 2 study evaluating Yescarta® in adult patients with relapsed or refractory indolent non-Hodgkin lymphoma after at least two prior lines of therapy.

Regeneron Pharmaceuticals, Inc. announced new results for higher dose level cohorts of its investigational REGN5458 bispecific antibody, which were presented in an oral session at the 2021 American Society of Hematology Annual Meeting in Atlanta, GA.

As the COVID-19 pandemic continues to evolve, five studies being presented during the 63rd American Society of Hematology Annual Meeting and Exposition shed light on the persisting burden that COVID-19 has had on people with underlying blood disorders.

Daiichi Sankyo Company, Limited announced that valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, demonstrated promising response rates in a pivotal phase 2 study in Japanese patients with relapsed/refractory adult T-cell leukemia/lymphoma.

BeiGene, a global, science-driven biotechnology company focused on developing innovative and affordable medicines, presented additional safety and efficacy results from an ongoing Phase 2 trial evaluating BRUKINSA® in patients with previously treated B-cell malignancies who were intolerant to ibrutinib and/or acalabrutinib.

Ichnos Sciences Inc., a global biotechnology company developing innovative biologics in oncology, presented preclinical data that support the potential for ISB 1442, a first-in-class 2+1 biparatopic bispecific antibody that targets both CD38 and CD47, as a treatment for relapsed/refractory multiple myeloma and other CD38+ hematological malignancies.

Karyopharm Therapeutics Inc. announced an oral presentation highlighting updated data from the Phase 2 ESSENTIAL study, an investigator-sponsored study evaluating single-agent selinexor, a first-in-class, oral Selective Inhibitor of Nuclear Export compound, in patients with myelofibrosis previously treated with JAK inhibition.

MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG, and Incyte announced additional real-world evidence results from the RE-MIND2 study comparing tafasitamab in combination with lenalidomide against the most frequently used treatments in adult patients with relapsed or refractory diffuse large B-cell lymphoma.